Profil
Rachel H.
Rondinelli worked as a Senior Director-IP & Licensing at Cenix BioScience GmbH.
She earned a doctorate degree from Michigan State University in 1994 and an undergraduate degree from Millersville University in 1989.
Anciens postes connus de Rachel H. Rondinelli
Sociétés | Poste | Fin |
---|---|---|
Cenix BioScience GmbH
Cenix BioScience GmbH Miscellaneous Commercial ServicesCommercial Services Cenix BioScience is a contract research organization specialized in combining advanced applications of RNAi with high content phenotypic analyses to enhance and accelerate the discovery and pre-clinical development of novel therapeutics. Cenix has built up a solid track record, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully-customized, cutting-edge research offerings covering a wide range of disease fields. The well-established core capabilities in high throughput RNAi and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured cell models, and are now complemented by microRNA-focused experimentation and in vivo applications of synthetic siRNAs. As such, Cenix is a mature and fully-proven industrial research provider, applying the highest of scientific best practices and offering a breadth and depth of expertise second to none world wide | Corporate Officer/Principal | - |
Formation de Rachel H. Rondinelli
Michigan State University | Doctorate Degree |
Millersville University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Cenix BioScience GmbH
Cenix BioScience GmbH Miscellaneous Commercial ServicesCommercial Services Cenix BioScience is a contract research organization specialized in combining advanced applications of RNAi with high content phenotypic analyses to enhance and accelerate the discovery and pre-clinical development of novel therapeutics. Cenix has built up a solid track record, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully-customized, cutting-edge research offerings covering a wide range of disease fields. The well-established core capabilities in high throughput RNAi and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured cell models, and are now complemented by microRNA-focused experimentation and in vivo applications of synthetic siRNAs. As such, Cenix is a mature and fully-proven industrial research provider, applying the highest of scientific best practices and offering a breadth and depth of expertise second to none world wide | Commercial Services |